Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IPG7236 / Immunophage Biotech
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors	Recruiting	1/2	196	US, RoW	IPG7236	Nanjing Immunophage Biotech Co., Ltd	Safety Issues, Tolerability, Pharmacokinetics	09/25	12/25
NCT05288543: A Study of Orally Administered IPG7236 in Healthy Adult Participants	Not yet recruiting	1	86	RoW	IPG7236- Single ascending dose, IPG7236- Multiple ascending dose, Placebo (Part A)	Nanjing Immunophage Biotech Co., Ltd, Novotech (Australia) Pty Limited	Atopic Dermatitis	10/22	11/22
IPG1094 / Immunophage Biotech
NCT06212076: Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients	Not yet recruiting	1/2	60	RoW	IPG1094	Nanjing Immunophage Biotech Co., Ltd	Solid Tumor	07/24	08/24
NCT05112159: Study of IPG1094 in Healthy Participants	Recruiting	1	46	RoW	IPG1094, placebo	Nanjing Immunophage Biotech Co., Ltd	Safety Issues	05/22	07/22
IPG0521 / Immunophage Biotech
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
IPG7236 / Immunophage Biotech
NCT05142592: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors	Recruiting	1/2	196	US, RoW	IPG7236	Nanjing Immunophage Biotech Co., Ltd	Safety Issues, Tolerability, Pharmacokinetics	09/25	12/25
NCT05288543: A Study of Orally Administered IPG7236 in Healthy Adult Participants	Not yet recruiting	1	86	RoW	IPG7236- Single ascending dose, IPG7236- Multiple ascending dose, Placebo (Part A)	Nanjing Immunophage Biotech Co., Ltd, Novotech (Australia) Pty Limited	Atopic Dermatitis	10/22	11/22
IPG1094 / Immunophage Biotech
NCT06212076: Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients	Not yet recruiting	1/2	60	RoW	IPG1094	Nanjing Immunophage Biotech Co., Ltd	Solid Tumor	07/24	08/24
NCT05112159: Study of IPG1094 in Healthy Participants	Recruiting	1	46	RoW	IPG1094, placebo	Nanjing Immunophage Biotech Co., Ltd	Safety Issues	05/22	07/22
IPG0521 / Immunophage Biotech
No trials found